BRCA2 and familial atypical multiple mole melanoma syndrome: Although our study was geared towards guiding PAC screening in BRCA2 mutation carriers, our findings suggest that screening may be effective in other patients or cohorts with genetic syndromes such as Familial Atypical Multiple Mole Melanoma Syndrome and Peutz–Jeghers Syndrome, which are less prevalent but are associated with extremely high risks of PAC; the optimal screening regimen, however, would need to be analyzed in separate analyses.